(Total Views: 599)
Posted On: 04/24/2021 7:40:52 AM
Post# of 145890
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
My impression from the proactive interview is that the added data for cd12 is to fill in holes from the original endpoint to make the trial significant. I am also assuming the fda has already strongly told cytodyn this is not going to be enough. The trials in India and Brazil must be a direct work around the us fda. Dr Jay’s letter to the fda must have been cleared with cytodyn, and as much as Nader reinforces a positive relationship with the FDA, the open letter is doing the heavy lifting to tell the FDA that this lack of an EUA is BS in an un-official way.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)